Elizabeth Nagelin-Anderson, MA and Diana Zuckerman, PhD, National Center for Health Research
How risky are breast implants? This is a controversial question, but implant manufacturers have done research showing that local complications, including pain, rupture, and the need for additional surgery, are very common within the first three years.
The FDA required breast implant manufacturers Mentor Corporation and Inamed Aesthetics (formerly called McGhan) to conduct research on the complications of saline breast implants for breast reconstruction and breast augmentation patients. The purpose of this research was to provide women with information so that they can make a more informed decision about whether or not they want saline breast implants. This information is supposed to be made available by plastic surgeons to all patients before they make their decision. The studies did not include diseases or conditions such as cancer, lupus, or fibromyalgia.
This issue brief is based on the FDA’s analyses of data collected by Mentor Corporation and Inamed Aesthetics. It is based on research, not opinion. The 3-year data were analyzed by the FDA in 2000 and the 5-year data were analyzed in 2002. This fact sheet is only about reconstruction patients.
Mentor Saline Implants
Mentor conducted a 5-year study on reconstruction patients. Unfortunately, so many women (almost 60%) dropped out of the study before the five years were completed, that the information is not reliable. For that reason, we are only providing the information collected during the first 3 years after getting implants, which included 78% of the patients.
Important Points from the Mentor Data
- Most women can expect at least one complication within the first 3 years.
- 40% of reconstruction patients can expect to have additional surgery within the first 3 years.
Mentor Reconstruction Patients 3-Year Complication Rate
Reconstruction patients experienced the following problems within the first 3 years of receiving their implants:
Only 78% of the reconstruction patients who originally enrolled in the study completed all 3 years. Women who had their implants removed, and women who left the study for any reason were not followed. Complications were measured up until a woman left the study, but percentages were based on the total number of women who started the study. So, the complication rate is actually even higher.
Inamed Saline Implants
Inamed, formerly called McGhan, conducted a 5-year study on breast reconstruction patients. They collected information at the 3-year point from 71% of the reconstruction patients who originally enrolled in the study.
At the 5-year point they collected information from 57% of the reconstruction patients. This is a problem, since no information is available for 43% of the patients. Women who had their implants removed, and women who left the study for any reason were not followed. Complications were measured up until a woman left the study, but percentages were based on the total number of women who started the study. So, the complication rate is actually even higher, and the 3-year data are more reliable than the 5-year data.
Important Points from the Inamed Data
- Most women can expect to experience at least one complication at some point within 5 years after implant surgery.
- 40% of reconstruction patients can expect to have additional surgery within the first 5 years.
Inamed Reconstruction Patients 3-Year and 5-Year Complication Rates
Reconstruction patients experienced the following complications during the first three years and first five years after surgery.
*Loss of nipple sensation is not listed since nipples are removed during mastectomy.
Most complications for Inamed patients through the first 5 years are similar to those reported after the first 3 years. Since it is well known that some complications, such as rupture and capsular contracture, increase over time, women with complications were apparently more likely to leave the study than those who continued. Some of these women have left their plastic surgeons and could not be contacted.
Read the mentor educational brochure here
Read the Inamed publication on making an informed decision here
Read the FDA’s list of potential local complications here
Read the FDA’s warning about ALCL here
All articles are reviewed and approved by Diana Zuckerman, PhD, and other senior staff.